MedPath

Mavoglurant

Generic Name
Mavoglurant
Drug Type
Small Molecule
Chemical Formula
C19H23NO3
CAS Number
543906-09-8
Unique Ingredient Identifier
GT0I9SV4F6
Background

Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).

Clinical Trials
Related News

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Phase 2
Recruiting
Conditions
Alcohol Consumption
Alcohol Use Disorder (AUD)
Heavy Drinker
Interventions
First Posted Date
2023-11-18
Last Posted Date
2024-08-15
Lead Sponsor
Yale University
Target Recruit Count
63
Registration Number
NCT06136195
Locations
🇺🇸

Connecticut Mental Health Center (SAC and SATU), New Haven, Connecticut, United States

🇺🇸

Yale New Haven Hospital, New Haven, Connecticut, United States

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Early Phase 1
Recruiting
Conditions
Familial Alcoholism Vulnerability
Interventions
Drug: Placebo
First Posted Date
2022-01-24
Last Posted Date
2024-05-23
Lead Sponsor
Yale University
Target Recruit Count
80
Registration Number
NCT05203965
Locations
🇺🇸

Hartford Hospital, Hartford, Connecticut, United States

Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056

Phase 1
Withdrawn
Conditions
Cocaine Use Disorder
Interventions
Drug: Placebo
First Posted Date
2021-02-25
Last Posted Date
2021-07-01
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT04771143

Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN

Early Phase 1
Completed
Conditions
Familial Alcoholism Vulnerability
Interventions
Other: Placebo
First Posted Date
2017-11-14
Last Posted Date
2022-01-11
Lead Sponsor
Yale University
Target Recruit Count
18
Registration Number
NCT03341715
Locations
🇺🇸

Hartford Hospital, Hartford, Connecticut, United States

Mavoglurant in Alcohol Drinking

Phase 1
Completed
Conditions
Alcohol Drinking
Interventions
Drug: Placebo
First Posted Date
2017-10-31
Last Posted Date
2024-08-06
Lead Sponsor
Yale University
Target Recruit Count
34
Registration Number
NCT03327792
Locations
🇺🇸

CMHC, Substance Abuse Center, New Haven, Connecticut, United States

Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)

Phase 2
Completed
Conditions
Cocaine-related Disorder
Interventions
Drug: Placebo
First Posted Date
2017-08-08
Last Posted Date
2021-10-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
68
Registration Number
NCT03242928
Locations
🇨🇭

Novartis Investigative Site, Zuerich, Switzerland

AFQ056 for Language Learning in Children With FXS

Phase 2
Completed
Conditions
Fragile X Syndrome
Interventions
Drug: Placebo
Other: Language Intervention
First Posted Date
2016-09-30
Last Posted Date
2023-10-10
Lead Sponsor
Elizabeth Berry-Kravis
Target Recruit Count
110
Registration Number
NCT02920892
Locations
🇺🇸

St Louis Children's Hospital (Washington University School of Medicine), Saint Louis, Missouri, United States

🇺🇸

Univeristy of California - Davis, Davis, California, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

and more 11 locations

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Phase 2
Terminated
Conditions
Failed SSRI Over 12 Weeks at Appropriate Doses
Patient Diagnosed With OCD and Resistant to SSRI Treatment
Interventions
Drug: Placebo
First Posted Date
2013-03-18
Last Posted Date
2017-01-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
50
Registration Number
NCT01813019
Locations
🇨🇭

Novartis Investigative Site, Bern, Switzerland

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Phase 2
Completed
Conditions
Parkinsonian Disorders
Anti-Dyskinesia Agents
Parkinson Disease
Dyskinesias
Movement Disorders
Interventions
First Posted Date
2011-12-14
Last Posted Date
2020-12-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
129
Registration Number
NCT01491932
Locations
🇨🇭

Novartis Investigative Site, Bern, Switzerland

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Phase 2
Completed
Conditions
Parkinson Disease
Parkinsonian Disorders
Anti-Dyskinesia Agents
Dyskinesias
Movement Disorders
Interventions
Drug: Placebo
First Posted Date
2011-12-14
Last Posted Date
2020-12-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
154
Registration Number
NCT01491529
Locations
🇨🇭

Novartis Investigative Site, Lausanne, Switzerland

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy